ID   UACC62R
AC   CVCL_WU69
DR   cancercelllines; CVCL_WU69
DR   GEO; GSM3195613
DR   GEO; GSM3195614
DR   Wikidata; Q98133801
RX   DOI=10.1101/381806;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1780 ! UACC-62
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 05-10-23; Version: 6
//
RX   DOI=10.1101/381806;
RA   Misek S.A., Appleton K.M., Dexheimer T.S., Lisabeth E.M., Lo R.S.,
RA   Larsen S.D., Gallo K.A., Neubig R.R.;
RT   "Rho-mediated MRTF and YAP1 activation contributes to BRAF inhibitor
RT   resistance in Sox9High/Sox10Low melanoma cells.";
RL   bioRxiv 2018:381806-381806(2018).
//